The contribution of nt-gp96 as an adjuvant for increasing hpv16 e7-specific immunity in c57bl/6 mouse model

Scandinavian Journal of Immunology

Volumn 75, Issue 1, 2012, Pages 27-37

  Mohit, E ^a   Bolhassani, A ^a   Zahedifard, F ^a   Taslimi, Y ^a   Rafati, S ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL GLYCOPROTEIN GP 96; GAMMA INTERFERON; GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; PROTEIN E7; PROTEIN E7 AMINO TERMINAL GLYCOPROTEIN GP 96 FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER MODEL; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TH1 CELL; TUMOR IMMUNITY; UTERINE CERVIX CANCER;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPROTEINS; HUMAN PAPILLOMAVIRUS 16; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; STATISTICS, NONPARAMETRIC; UTERINE CERVICAL NEOPLASMS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 83455211267     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02620.x     Document Type: Article

References (59)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Bolhassani A, Mohit E, Rafati S. Different spectra of therapeutic vaccine development against HPV infections. Hum Vaccin 2009;5:671-89.
3. Lin K, Doolan K, Hung CF, Wu TC. Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 2010;109:4-24.
4. Su JH, Wu A, Scotney E et al. Immunotherapy for cervical cancer: research status and clinical potential. BioDrugs 2010;24:109-29.
5. Bolhassani A, Rafati S. Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines 2008;7:1185-99.
6. Segal BH, Wang XY, Dennis CG et al. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov Today 2006;11:534-40.
7. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002;2:185-94.
8. Wang HH, Mao CY, Teng LS, Cao J. Recent advances in heat shock protein-based cancer vaccines. Hepatoobiliary Pancreat Dis Int 2006;5:22-7.
9. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278:117-20.
10. Moroi Y, Mayhew M, Trcka J et al. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci U S A 2000;97:3485-90.
11. Gong J, Zhang Y, Durfee J et al. A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use. J Immunol 2010;184:488-96.
12. Yang Y, Li Z. Roles of heat shock protein gp96 in the ER quality control: redundant or unique function? Mol Cells 2005;20:173-82.
13. Mazzarella RA, Green M. ERp99, an abundant, conserved glycoprotein of the endoplasmic reticulum, is homologous to the 90-kDa heat shock protein (hsp90) and the 94-kDa glucose regulated protein (GRP94). J Biol Chem 1987;262:8875-83.
14. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000;1:151-5.
15. Singh-Jasuja H, Toes RE, Spee P et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class i molecules requires receptor-mediated endocytosis. J Exp Med 2000;191:1965-74.
16. Ramirez SR, Singh-Jasuja H, Warger T et al. Glycoprotein 96-activated dendritic cells induce a CD8-biased T cell response. Cell Stress Chaperones 2005;10:221-9.
17. Singh-Jasuja H, Hilf N, Scherer HU et al. The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells. Cell Stress Chaperones 2000;5:462-70.
18. Vogen S, Gidalevitz T, Biswas C et al. Radicicol-sensitive peptide binding to the Nterminal portion of GRP94. J Biol Chem 2002;277:40742-50.
19. Biswas C, Sriram U, Ciric B, Ostrovsky O, Gallucci S, Argon Y. The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigenpresenting cells. Int Immunol 2006;18:1147-57.
20. Li HT, Yan JB, Li J et al. Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice. World J Gastroenterol 2005;11:2858-63.
21. Li H, Zhou M, Han J et al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol 2005;174:195-204.
22. Yan J, Liu X, Wang Y et al. Enhancing the potency of HBV DNA vaccines using fusion genes of HBV-specific antigens and the N-terminal fragment of gp96. J Gene Med 2007;9:107-21.
23. Wang L, Rollins L, Gu Q, Chen SY, Huang XF. A mage3/heat shock protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity. Vaccine 2009;28:561-70.
24. Suzue K, Young RA. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol 1996;156:873-9.
25. Suzue K, Zhou X, Eisen HN, Young RA. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci U S A 1997;94:13146-51.
26. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 1998;78:41-5.
27. Bolhassani A, Zahedifarda F, Taghikhani M, Rafati S. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies. Vaccine 2008;26:3362-70.
28. Ortiz ML, Calero M, Patron CF, Castellanos L, Mendez E. Imidazole-SDS-Zn reverse staining of proteins in gels containing or not SDS and microsequencing of individual unmodified electroblotted proteins. FEBS Lett 1992;296:300-4.
29. Li Y, Subjeck J, Yang G, Repasky E, Wang XY. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine 2006;24:5360-70.
30. Ma B, Xu Y, Hung CF, Wu TC. HPV and therapeutic vaccines: where are we in 2010? Curr Cancer Ther Rev 2010;6:81-103.
31. Lacey CJ, Thompson HS, Monteiro EF et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 1999;179:612-8.
32. de Jong A, O'Neill T, Khan AY et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 2002;20:3456-64.
33. Hallez S, Simon P, Maudoux F et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 2004;53:642-50.
34. Frazer IH, Quinn M, Nicklin JL et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004;23:172-81.
35. Li J, Li KN, Gao J, Cui JH, Liu YF, Yang SJ. Heat shock protein 70 fused to or complexed with hantavirus nucleocapsid protein significantly enhances specific humoral and cellular immune responses in C57BL/6 mice. Vaccine 2008;26:3175-87.
36. Ge FF, Qiu YF, Yang YW, Chen PY. An hsp70 fusion protein vaccine potentiates the immune response against Japanese encephalitis virus. Arch Virol 2007;152:125-35.
37. Chandawarkar R, Wagh M, Kovalchin J, Srivastava P. Immune modulation with high-dose heatshock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis. Int Immunol 2004;16:615-24.
38. Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003;9:3235-45.
39. Belli F, Testori A, Rivoltini L et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002;20:4169-80.
40. Maki RG, Livingston PO, Lewis JJ et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 2007;52:1964-72.
41. Oki Y, McLaughlin P, Fayad LE et al. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 2007;109:77-83.
42. Baker-LePain JC, Sarzotti M, Nicchitta CV. Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo. J Immunol 2004;172:4195-203.
43. Maniero GD, Robert J. Phylogenetic conservation of gp96-mediated antigen-specific cellular immunity: new evidence from adoptive cell transfer in xenopus. Transplantation 2004;78:1415-21.
44. Robert J, Ramanayake T, Maniero GD, Morales H, Chida AS. Phylogenetic conservation of glycoprotein 96 ability to interact with CD91 and facilitate antigen cross-presentation. J Immunol 2008;180:3176-82.
45. Chu NR, Wu HB, Wu TC et al. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacilli Calmette±GueÂrin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 2000;121:216-25.
46. Ma JH, Sui YF, Ye J et al. Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo. Cancer Immunol Immunother 2005;54:907-14.
47. Dominiecki ME, Beatty GL, Pan ZK, Neeson P, Paterson Y. Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunol Immunother 2005;54:477-88.
48. Ding Y, Seow SV, Huang CH et al. Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity. Immunology 2009;128:e881-94.
49. Palefsky JM, Berry JM, Jay N et al. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 2006;20:1151-5.
50. Einstein MH, Kadish AS, Burk RD et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007;106:453-60.
51. Roman LD, Wilczynski S, Muderspach LI et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007;106:558-66.
52. Cho BK, Palliser D, Guillen E et al. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity 2000;12:263-72.
53. Gong X, Gai W, Xu J, Zhou W, Tien P. Glycoprotein 96-mediated presentation of human immunodeficiency virus type 1 (HIV-1)-specific human leukocyte antigen class I-restricted peptide and humoral immune responses to HIV-1 p24. Clin Vaccine Immunol 2009;16:1595-600.
54. Liu B, Ye D, Song X et al. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine 2008;26:1387-96.
55. Pakravan N, Hashemi SM, Hassan ZM. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent. Cell Stress Chaperones 2011;16:41-8.
56. Peng S, Trimble C, Ji H et al. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J Biomed Sci 2005;12:689-700.
57. Bungener L, de Mare A, de Vries-Idema J et al. A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease. Antivir Ther 2006;11:717-27.
58. Gérard CM, Baudson N, Kraemer K et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 2001;19:2583-9.
59. Stewart TJ, Drane D, Malliaros J et al. ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine 2004;22:3738-43.